{
    "organizations": [],
    "uuid": "6ad55b8932fe1b228227c629069c5569005f5631",
    "author": "Aisha Al-Muslim",
    "url": "https://www.wsj.com/articles/fda-approves-first-nonopioid-treatment-for-opioid-withdrawal-symptoms-1526510659",
    "ord_in_thread": 0,
    "title": "FDA Approves First Nonopioid Treatment for Opioid Withdrawal Symptoms",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "The U.S. Food and Drug Administration has approved the first nonopioid treatment to help adults manage opioid withdrawal symptoms as the agency looks to continue to encourage the development of therapies to help patients suffering from addiction.\nThe FDA granted the approval of Lucemyra to Louisville, Ky.-based pharmaceutical company US WorldMeds LLC, the agency said Wednesday. The company also develops products for patients with Parkinsonâ€™s disease, malignant hyperthermia and other medical conditions.\n... ",
    "published": "2018-05-17T03:11:00.000+03:00",
    "crawled": "2018-05-17T03:45:42.030+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "food",
        "drug",
        "administration",
        "approved",
        "first",
        "nonopioid",
        "treatment",
        "help",
        "adult",
        "manage",
        "opioid",
        "withdrawal",
        "symptom",
        "agency",
        "look",
        "continue",
        "encourage",
        "development",
        "therapy",
        "help",
        "patient",
        "suffering",
        "addiction",
        "fda",
        "granted",
        "approval",
        "lucemyra",
        "louisville",
        "pharmaceutical",
        "company",
        "u",
        "worldmeds",
        "llc",
        "agency",
        "said",
        "wednesday",
        "company",
        "also",
        "develops",
        "product",
        "patient",
        "parkinson",
        "disease",
        "malignant",
        "hyperthermia",
        "medical",
        "condition"
    ]
}